Cancer Management and Research最新文献

{"title":"Characteristics and Outcomes of Soft Tissue Sarcoma in Saudi Arabia: A 10-Year Experience.","authors":"Bader Alshamsan, Omar I Alrifai, Mohammad A Altayeb, Mohammed M Alobud, Aiman Alshomrani, Nouf F Alsadoun, Rashed Bin Khidhr, Rajeev Pant, Mahmood Shaheen, Jean Paul Atallah","doi":"10.2147/CMAR.S530633","DOIUrl":"10.2147/CMAR.S530633","url":null,"abstract":"<p><strong>Purpose: </strong>Soft tissue sarcomas (STS) are rare, heterogeneous malignancies representing less than 1% of solid cancers. Given the diversity of subtypes and the complexity of management, understanding regional epidemiological patterns is essential. This study aimed to evaluate the clinical characteristics, treatment strategies, and prognostic factors in STS patients in Saudi Arabia at a sarcoma center.</p><p><strong>Patients and methods: </strong>This retrospective study included 214 patients with STS treated between 2010 and 2020. Patient demographics, tumor characteristics, clinical stage, and treatment modalities were collected using REDCap. Overall survival (OS) was estimated using Kaplan-Meier curves, and prognostic factors were analyzed using Cox regression. Statistical significance was set at p < 0.05.</p><p><strong>Results: </strong>The median age at diagnosis was 37 years (IQR: 25-49.5), and the median symptom duration before diagnosis was 8 months. Synovial sarcoma (20%) was the most common subtype, followed by liposarcoma (13.6%) and undifferentiated pleomorphic sarcoma (12%). Metastatic disease at diagnosis was reported in 39% of patients, with the lower limb being the most affected site (62.1%). Local treatment included surgery alone (45.3%), radiation alone (7.5%), and combined surgery and radiation (41.6%). Median OS was not reached in localized disease, whereas it was 26 months in metastatic cases (p< 0.01). Age ≥65 years (hazard ratio[HR]: 6.05, p=0.002), larger tumor size (HR: 9.12, p=0.04), and metastasis (HR: 8.77, p<0.001) were associated with worse survival. Tumors in extremities (HR: 0.38, p=0.04) and combined local therapy (HR: 0.13, p=0.009) were associated with better OS. Multimodal therapy improved OS in metastatic cases (p=0.004).</p><p><strong>Conclusion: </strong>STS in Saudi Arabia presents at a younger age, with prolonged symptom duration, and a high burden of metastatic disease. Despite these challenges, outcomes are comparable to global trends, particularly multimodal approaches. Future research should identify barriers to early diagnosis, improve healthcare access, and explore novel systemic therapies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1999-2008"},"PeriodicalIF":2.6,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145111969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parotid Lymph Node Metastasis Prediction of Nasopharyngeal Carcinoma Based on Ultrasound Radiomics Analysis.","authors":"Xingzhang Long, Yao Xue, Ruhai Zou, Shangman Yang, Zhong Liu, Qicai Huang, Chuan Peng, Xu Han, Weixuan Kong, Wei Zheng","doi":"10.2147/CMAR.S526722","DOIUrl":"10.2147/CMAR.S526722","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the clinical utility of ultrasound radiomics in predicting parotid lymph node metastasis (PLNM) in nasopharyngeal carcinoma (NPC) patients.</p><p><strong>Methods: </strong>Grayscale ultrasound (US) images of parotid gland nodules were segmented, and radiomics features were extracted. An support vector machine (SVM) model was built using the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm for feature selection. Different SVM models were built based on clinical characteristics, radiomics features, and a combination of these features. Performance of the models was assessed using the area under the curve (AUCs), sensitivity and specificity.</p><p><strong>Results: </strong>Among 406 patients (192 PLNM, 214 benign), a total of 406 nodules were included in this study. Thirty-one radiomics features were selected as significant using the LASSO algorithm from the 474 extracted radiomics features. In the clinical model, NPC patients with suspicious parotid gland nodules of irregular shape, poorly defined margins, long/short axis ratio (LSR) <1, and posterior acoustic enhancement (PAE) were significant variables for PLNM (p<0.05). In the validation dataset, the AUC were 0.916 (95% CI: 0.876-0.983) in the clinical model, 0.830 (95% CI: 0.784-0.872) in the single radiomics model, and 0.928 (95% CI: 0.792-0.945) in the combined model. The calibration curve of the different models and decision curve analysis (DCA) demonstrated the diagnostic performance of the combined model.</p><p><strong>Conclusion: </strong>The combined model using ultrasound radiomics has clinical utility in identifying useful US features and enhancing the diagnostic accuracy of ultrasound for detecting PLNM in patients with NPC.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1971-1980"},"PeriodicalIF":2.6,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable Control of Multi-Refractory HBV-HCC with Bevacizumab/Sintilimab/Lenvatinib Triplet Therapy.","authors":"Jian Wang, Junhui Wang, Jianxin Chen","doi":"10.2147/CMAR.S547885","DOIUrl":"10.2147/CMAR.S547885","url":null,"abstract":"<p><strong>Background: </strong>Advanced HCC progressing after standard first-line immune checkpoint inhibitor (ICI)/antiangiogenic therapy and second-line tyrosine kinase inhibitors (TKIs) has limited treatment options.</p><p><strong>Case presentation: </strong>A 67-year-old male with HBV-related HCC (cT2N1M0, Child-Pugh B) exhibited rapid progression after transarterial chemoembolization, bevacizumab/sintilimab, and lenvatinib monotherapy. Salvage triplet therapy with bevacizumab (400 mg IV q3w), sintilimab (200 mg IV q3w), and lenvatinib (8 mg daily) achieved >50% alpha-fetoprotein (AFP) reduction within two cycles and sustained radiologic disease stabilization for 10 months, with only grade 1 fatigue and hemoptysis.</p><p><strong>Conclusion: </strong>This is the first documented case of bevacizumab/sintilimab/lenvatinib triplet efficacy in triple-class refractory HCC, suggesting potential synergistic mechanisms and feasibility even in Child-Pugh B patients. These findings warrant further investigation in prospective studies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1981-1987"},"PeriodicalIF":2.6,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatics Analysis and Experimental Validation of Lactylation Related Genes in Lung Adenocarcinoma.","authors":"Li Gao, Yadi Zhang, Fengrui Wu, Bin Liu, Xin Xie","doi":"10.2147/CMAR.S533289","DOIUrl":"10.2147/CMAR.S533289","url":null,"abstract":"<p><strong>Purpose: </strong>Lactylation, a novel post-translational modification, is dysregulated in various tumors and influences lung cancer progression. However, its role in lung adenocarcinoma (LUAD) remains unclear. Based on multi-omics analysis results, this study investigated lactylation levels in LUAD tissues and explored the dual research positioning of lactylation as a prognostic marker and therapeutic target.</p><p><strong>Methods: </strong>Lactylation levels in LUAD tissue microarrays were assessed using immunohistochemistry and immunofluorescence. Western blot analysis validated these findings. Differential expression analysis of lactylation-related genes was conducted using The Cancer Genome Atlas (TCGA, n=365), based on |log2 fold-change (FC)|≥2. KEGG pathway analysis identified key biological pathways, and COX regression analysis pinpointed prognostic genes. Single-cell RNA sequencing data from the GEO database validated these genes, with mitochondrial gene threshold <20%.</p><p><strong>Results: </strong>Lactylation levels were significantly elevated in LUAD tissues compared to adjacent non-cancerous tissues, as shown by immunohistochemistry and confirmed by Western blot analysis. Differential analysis identified 17 lactylation-related genes enriched in pathways such as AMPK signaling and cellular senescence. COX regression analysis identified five risk genes: KIF2C, MKI67, HMGA1, PFKP, and CCNA2. Validation with single-cell RNA sequencing data revealed high expression levels of these genes in LUAD tissues and the LUAD cell line H1299. Functional validation revealed that the 5 genes panel significantly regulates global lactylation modification in vitro.</p><p><strong>Conclusion: </strong>LUAD tissues exhibit elevated lactylation levels, suggesting their potential as prognostic biomarkers. The identified genes-KIF2C, MKI67, HMGA1, PFKP, and CCNA2-are highly expressed in cancerous tissues and correlate with LUAD prognosis. These findings highlight their value as tumor biomarkers and therapeutic targets, offering new opportunities for targeted LUAD treatments.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1947-1960"},"PeriodicalIF":2.6,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SMARCA2 Deficiency While Preserving SMARCA4 in Lung Adenocarcinoma Combined with Abnormal β-Catenin Expression.","authors":"Xiaomin Dai, Xiaoyue Feng, Jing Li, Fang Peng","doi":"10.2147/CMAR.S533790","DOIUrl":"10.2147/CMAR.S533790","url":null,"abstract":"<p><strong>Background: </strong>The SWI/SNF complex is comprised of ATPase catalytic subunit SMARCA4/SMARCA2, evolutionarily conserved core subunits including SMARCB1, SMARCC1, and SMARCC2, as well as functionally specialized accessory subunits PBRM1 and ARID1A. Deletion or mutation of the catalytic subunit can lead to inactivation of the encoded protein and impaired overall function of the complex, contributing to tumorigenesis.</p><p><strong>Methods: </strong>In this study, we conducted a retrospective analysis of seven cases of poorly differentiated lung adenocarcinoma from our institution that exhibited SMARCA2 deficiency while retaining SMARCA4 expression, and systematically evaluated the clinical characteristics, histological features, genetic alterations, and survival outcomes.</p><p><strong>Results: </strong>Among the seven cases of SMARCA2-deficient lung adenocarcinoma, five were male and two were female, with an average age of 68.7 years. Four patients had a smoking history averaging 35 years, all seven patients exhibited respiratory symptoms. Histologically, these tumors displayed diverse features, including rhabdoid morphology, giant cells, and necrotic areas. The tumor cells exhibited eosinophilic cytoplasm, large nuclei with prominent nucleoli. Immunohistochemically, the tumor cells revealed SMARCA2 negativity with SMARCA4 expression. P53 staining revealed diffuse strong nuclear expression in 5 cases and complete absence expression in 2 cases. β-catenin expression was partially abnormal in 3 cases, with positive nuclear and cytoplasmic staining. PD-L1 expression was detected as positive in 5 cases. Next-generation sequencing identified mutations in driver genes KRAS, MET, and EGFR in 4 cases, and TP53 mutations in 7 cases. Clinical follow-up revealed that 2 patients died of tumor progression, 5 patients achieved complete response within a follow-up period of 10 to 33 months (median = 18.3 m).</p><p><strong>Conclusion: </strong>SMARCA2-deficient with SMARCA4-preserved lung adenocarcinomas demonstrate substantial histological heterogeneity and may dedifferentiate into high-grade adenocarcinomas harboring TP53 mutations. In the assessment of poorly differentiated lung adenocarcinoma, immunohistochemical detection can identify this subtype for more precise clinical treatment strategies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1961-1970"},"PeriodicalIF":2.6,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefit Finding: The Mediator Linking Social Support to Self - Management Efficacy in Gynecological Cancer.","authors":"Rongrong Liu, Linzhi Jiang, Fan Wang, Xingqun Tan, Liyuan Sun","doi":"10.2147/CMAR.S540258","DOIUrl":"10.2147/CMAR.S540258","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the relationships among benefit finding (BF), self-management efficacy, and social support in patients with gynecologic cancers.</p><p><strong>Methods: </strong>A total of 180 patients with gynecological cancer were selected using a convenience sampling methodology from Maternal and Child Health Hospital in Shenzhen, China. The data collection tools included sociodemographic and disease-related information, the Chinese Version of the Benefit Finding Scale (BFS), the Chinese Self-Management Efficacy Scale for Cancer Patients (C-SUPPH), and the Social Support Rating Scale (SSRS). Data analysis involved descriptive statistics, independent-samples t-tests, one-way ANOVA, Pearson correlation analysis, and hierarchical multiple regression. The SPSS 29.0 and the PROCESS 4.2 macro were used to validate the mediating effects.</p><p><strong>Results: </strong>BF was positively correlated with social support (<i>r</i> = 0.235, <i>P</i> < 0.01) and self-management efficacy (<i>r</i> = 0.453, <i>P</i> < 0.01). Social support also showed a correlation with self-management efficacy (<i>r</i> = 0.268, <i>P</i> < 0.01). BF partially mediated the relationship between social support and self-management efficacy, accounting for 36.28% of the total effect.</p><p><strong>Conclusion: </strong>Self-management efficacy in patients with gynecological cancers is at a moderate level. Social support indirectly influences self-management efficacy through BF. Enhancing BF could serve as an effective strategy to improve self-management efficacy in this patient population.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1935-1945"},"PeriodicalIF":2.6,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Communication-Based Intervention Program Based on Narrative Medicine Theory Effectively Improves the Quality of Nursing Care for Nasopharyngeal Cancer Patients Undergoing Radiotherapy and Chemotherapy.","authors":"Xing-Li Liu, Bao-Zhu Chen, Yun-Ying Lin, Zhi-Xian Chen, Qiao-Hua Zhu","doi":"10.2147/CMAR.S521105","DOIUrl":"10.2147/CMAR.S521105","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of a communication-based intervention program rooted in narrative medicine theory on the quality of nursing care and patient outcomes in nasopharyngeal carcinoma patients undergoing radiotherapy and chemotherapy.</p><p><strong>Methods: </strong>This retrospective cohort study included 98 nasopharyngeal carcinoma patients treated at our hospital between September 2022 and August 2024. Patients were divided into two groups based on historical nursing records: the control group (n=49) received routine standard nursing care, while the observation group (n=49) received routine care supplemented with a narrative medicine-based communication intervention. The intervention was conducted 1-2 times per week over four consecutive weeks. Outcomes were assessed using the Fear of Progression Questionnaire-Short Form (FoP-Q-SF), Pittsburgh Sleep Quality Index (PSQI), Cancer Fatigue Scale (CFS), Herth Hope Index (HHI), Nursing Quality Evaluation Scale, and Communication Satisfaction Questionnaire, measured at baseline and post-intervention.</p><p><strong>Results: </strong>Compared to controls, the observation group showed significantly reduced fear of progression (FoP-Q-SF: 33.53 vs 43.11), improved sleep (PSQI: 11.25 vs 15.41), lower cancer-related fatigue (CFS total: 28.23 vs 35.94), and higher hope levels (HHI: 33.45 vs 25.56) (all p < 0.001). Nursing quality and communication satisfaction also improved significantly across all domains (p < 0.001).</p><p><strong>Conclusion: </strong>The communication-based intervention program based on narrative medicine significantly improves psychological well-being, sleep quality, cancer-related fatigue, hope level, and overall nursing quality in nasopharyngeal carcinoma patients undergoing radiotherapy and chemotherapy. This approach offers a feasible and effective model for enhancing holistic cancer care.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1925-1934"},"PeriodicalIF":2.6,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Modeling of Clinical Efficacy for ¹²⁵I Brachytherapy in Head and Neck Tumors Using Lasso-Logistic Regression.","authors":"Yun Liu, Lai Xu, Yakun Fang, Chao Yan","doi":"10.2147/CMAR.S524335","DOIUrl":"10.2147/CMAR.S524335","url":null,"abstract":"<p><strong>Background: </strong>In view of the differences in the clinical efficacy of ¹²⁵I radioactive particle brachytherapy for head and neck tumors, this study aims to systematically analyze the key factors affecting its efficacy, and build a reliable prediction model to provide a scientific basis for clinical precise evaluation and personalized treatment plan formulation.</p><p><strong>Methods: </strong>Retrospective analysis of 174 patients (2020-2024) divided into training (n=122) and validation (n=52) sets. Efficacy was assessed using RECIST criteria. Lasso Logistic regression identified independent factors, and a nomogram model was constructed and evaluated.</p><p><strong>Results: </strong>The study confirmed that patients' age, tumor stage, tumor diameter, particle implantation dose and serum tumor marker level were independent factors affecting the clinical efficacy (<i>P</i><0.05). The nomogram prediction model has excellent performance, and the c-index values in the training set and the validation set are 0.867 and 0.725, respectively, showing good discrimination ability; The results of calibration curve showed that the predicted value was in good agreement with the actual value, and the average absolute errors of the two groups were 0.114 and 0.133, respectively; In Hosmer lemeshow test, the training set <i>χ²</i> =7.422 (<i>P</i>=0.491), the validation set <i>χ²</i> =12.086 (<i>P</i>=0.147), suggesting that the model fitting effect is ideal; The area under the ROC curve in the training set and the validation set was 0.860 (95% CI:0.767-0.953) and 0.750 (95% CI:0.501-0.999), respectively, which showed high sensitivity and specificity.</p><p><strong>Conclusion: </strong>The model effectively predicts ¹²⁵I brachytherapy outcomes, aiding clinical evaluation and supporting precision treatment for head and neck tumors.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1911-1923"},"PeriodicalIF":2.6,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12423257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"lncRNA BANCR Suppresses Cell Viability and Invasion and Promotes Apoptosis in Non-Small-Cell Lung Cancer Cells in vitro and in vivo [Retraction].","authors":"","doi":"10.2147/CMAR.S564697","DOIUrl":"10.2147/CMAR.S564697","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/CMAR.S194848.].</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1909-1910"},"PeriodicalIF":2.6,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABO Blood Group and the Risk and Prognosis of Diffuse Large B-Cell Lymphoma.","authors":"Dongli Gao, Mingzhi Zhang, Shuxin Lv, Qinan Yin, Zhenchang Sun, Ling Qin","doi":"10.2147/CMAR.S531434","DOIUrl":"10.2147/CMAR.S531434","url":null,"abstract":"<p><strong>Background: </strong>Our previous research had demonstrated that there might exist a certain correlation between ABO blood group and lymphoma. This study aimed to investigate the influence of ABO blood group in diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>We retrospectively analyzed clinical data of 220 patients with newly diagnosed DLBCL. Chi-square test and Cox proportional hazard models were used to examine the association between ABO blood type and both the risk and prognosis of DLBCL.</p><p><strong>Results: </strong>In females, individuals who had blood type AB exhibited a higher propensity for developing DLBCL in comparison to those with blood type B (<i>P</i>=0.005). Notably, among DLBCL patients who were over the age of 60 years, those who had blood type B had significantly shorter 3-year overall survival (OS) compared to patients with non-B blood types (<i>P</i>=0.030). Conversely, among DLBCL patients aged 60 years or younger, no significant disparity in OS was observed between those with blood type B and non-B blood types (<i>P</i>= 0.196). Both univariate and multivariate Cox regression analyses were conducted on DLBCL patients who were over 60 years old. These analyses revealed that having blood type B served as a negative prognostic factor for this subset of patients.</p><p><strong>Conclusion: </strong>Females with blood type B may have a lower risk of developing DLBCL compared to females with blood type AB. For DLBCL patients older than 60 years, blood type B may be considered a poor prognostic factor.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1897-1907"},"PeriodicalIF":2.6,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}